Report Library
All ReportsDatamonitor Healthcare Strategy: Transforming Pharmaceutical R&D with Data
May 02, 2017
In the current drug pricing environment, biopharmaceutical firms cannot afford to continue spending billions of dollars on development
programs that are more than 90% likely to fail. Raising prices to compensate for expensive, risky research and development (R&D) is no
longer an option amid a global payer backlash against drug costs. Drug R&D needs to become more efficient, faster, and cost-effective in
order for biopharma firms to be sustainable and to maintain a supply of innovative treatments.
This Datamonitor Healthcare report contains a Strategy module.
This Datamonitor Healthcare report contains a Strategy module.
Disease Group Covered: | Not Specified |